Application seeking approval of brexucabtagene autoleucel (Tecartus) for relapsed or refractory acute lymphoblastic leukaemia submitted to the US FDA

Tecartus is an autologous, anti-CD19 CAR T cell therapy. The application is supported by data from the ongoing Phase I/II ZUMA-3 trial, investigating its use in adults with ALL whose disease is refractory to or has relapsed following standard systemic therapy or HSCT.

Source:

Biospace Inc.